He frankly doesn't appear to know what he is talking about. Simply follow MD&A from management, or the MST report;
"..2025 Launch, with peak sales assumed to be achieved within 4 years"
Its a repurposed drug with safety profiles well known, using a formulation already manufactured and passing all safety requirements via Peptron. Its not going to be given to millions of diabetes patients, reformulated to 240 patients for IIH in this trial, then sat for 2-3 years for MORE tests for an orphan indication.. he is clueless.
He frankly doesn't appear to know what he is talking about....
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.260M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28320 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 22452 | 2 |
View Market Depth
| Last trade - 10.04am 05/09/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable